May 15 - 16
The Hague, NL
Visit our booth #9
Meet the Lunaphore Team
Mark your calendars for the International Spatial Biology Congress in The Hague!
Join us and engage directly with our specialists to discover spatial multiomics on COMET™. Experience firsthand how you can detect RNA and proteins simultaneously. All within the same section, and at a subcellular level of detail.
Our protease-free, fully automated workflow enables multiomics scalability for all stages of research. Are you interested in elevating your spatial biology projects with our multiomics solutions? Visit us at booth 9 to find out more.
See below for Lunaphore’s schedule. More information can be found on the official website.
Posters and Presentations
May 15 - 16
Poster Presentation
May 15 - 16
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success.
To address this, we have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™, Rivest et al., 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and use standard, non-conjugated primary antibodies for protein detection. We used Lunaphore’s HORIZON™ software to analyze this multiomics dataset.
Here, we have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using cytokine RNA probes targeting IFNG, IL-1B, TNFA, TGFB1, IL-4, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68.In addition, we were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12, and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
To that end, we successfully demonstrated same-slide RNA-protein detection for profiling the TME. Using single-cell spatial multiomics, we were able to identify unique phenotypes within the tumors that might directly correlate to immunosuppressive or immunostimulatory microenvironments. Detailed mapping of the cellular components of the TME has the potential to better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Victoria Wosika, Ph.D.
Scientific Marketing Manager
Lunaphore Technologies
May 15, 12:15 PM
Sponsored Presentation
May 15
12:15 PM
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success.
To address this, we have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™, Rivest et al., 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and use standard, non-conjugated primary antibodies for protein detection. We used Lunaphore’s HORIZON™ software to analyze this multiomics dataset.
Here, we have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using cytokine RNA probes targeting IFNG, IL-1B, TNFA, TGFB1, IL-4, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68.In addition, we were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12, and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
To that end, we successfully demonstrated same-slide RNA-protein detection for profiling the TME. Using single-cell spatial multiomics, we were able to identify unique phenotypes within the tumors that might directly correlate to immunosuppressive or immunostimulatory microenvironments. Detailed mapping of the cellular components of the TME has the potential to better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Bastian Nicolai, M.Sc.
Product Manager
Lunaphore
He is a molecular biotechnologist and holds an M.Sc. from the RWTH Aachen University. After more than seven years in the life science arena, joining companies focusing on immunology, immuno-oncology, and nucleic acid sample and assay technologies, Bastian is now the Product Manager at Lunaphore Technologies SA, concentrating on the applications portfolio for the spatial biology platforms COMET™ and LabSat®.
May 15 - 16
Poster Presentation
May 15 - 16
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success.
To address this, we have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™, Rivest et al., 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and use standard, non-conjugated primary antibodies for protein detection. We used Lunaphore’s HORIZON™ software to analyze this multiomics dataset.
Here, we have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using cytokine RNA probes targeting IFNG, IL-1B, TNFA, TGFB1, IL-4, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68.In addition, we were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12, and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
To that end, we successfully demonstrated same-slide RNA-protein detection for profiling the TME. Using single-cell spatial multiomics, we were able to identify unique phenotypes within the tumors that might directly correlate to immunosuppressive or immunostimulatory microenvironments. Detailed mapping of the cellular components of the TME has the potential to better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Victoria Wosika, Ph.D.
Scientific Marketing Manager
Lunaphore Technologies
May 15, 12:15 PM
Sponsored Presentation
May 15
12:15 PM
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success.
To address this, we have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™, Rivest et al., 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and use standard, non-conjugated primary antibodies for protein detection. We used Lunaphore’s HORIZON™ software to analyze this multiomics dataset.
Here, we have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using cytokine RNA probes targeting IFNG, IL-1B, TNFA, TGFB1, IL-4, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68.In addition, we were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12, and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
To that end, we successfully demonstrated same-slide RNA-protein detection for profiling the TME. Using single-cell spatial multiomics, we were able to identify unique phenotypes within the tumors that might directly correlate to immunosuppressive or immunostimulatory microenvironments. Detailed mapping of the cellular components of the TME has the potential to better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Bastian Nicolai, M.Sc.
Product Manager
Lunaphore